NCT07168083View on ClinicalTrials.gov

Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression

Not yet recruitingOBSERVATIONAL

Enrollment

22

Participants

Timeline

Start Date

September 1, 2026

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2029

Conditions

Ovarian CancerAntibody-drug ConjugatesClear Cell Adenocarcinoma of Ovary

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER